BrightSpring Raises 2026 Guidance After Q3 Beat, Specialty and Home Health Drive Upside

What happened

BrightSpring's Q3 results surpassed expectations, prompting management to raise full-year 2026 guidance, as specialty drug launches and expanding home health census fueled outperformance. This development contrasts with the cautious stance in the prior DeepValue report, which highlighted declining pharmacy scripts and rising SG&A as key risks to the mix-led growth narrative. The Q3 beat suggests that specialty and infusion mix may be offsetting IRA-driven pressure in home and community pharmacy, while provider services ADC continues to scale without M&A. However, the news summary lacks specifics on total prescription trends and SG&A discipline, leaving open whether the core concerns of script volume and cost control have been resolved. The raised guidance also does not address the ongoing sponsor overhang, with KKR still holding a significant stake and potential post-lock-up selling pressure in early August 2026.

Implication

The raised guidance and Q3 beat shift the risk-reward slightly in BrightSpring's favor, moving the base-case implied value potentially above $68. However, the stock's current valuation at ~26x EV/EBITDA leaves little room for error if sponsorship supply or cost growth re-accelerates. The key for investors is whether specialty drug launches and home health gains are sustainable and whether total pharmacy scripts recover to flat or positive. Until Q3 details confirm script trends and SG&A moderation, the asymmetric downside from sponsor overhang and policy drags remains. A prudent stance is to maintain a WAIT, with an attractive entry near $55 and a trim level above $75, while monitoring for evidence of broad-based volume growth.

Thesis delta

The Q3 beat and raised guidance modestly strengthen the bull case, suggesting that specialty mix and home health momentum are offsetting pharmacy script weaknesses. However, the absence of script and cost details in the summary prevents a full thesis upgrade; the core concerns of declining total scripts and elevated SG&A are not yet resolved. Therefore, the WAIT rating stands, but the probability of the bull scenario increases if Q3 data confirm stabilizing scripts and controlled spending.